Analyst Reco. Pulmonx Corporation

Equities

LUNG

US7458481014

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
7.28 ^USD	-0.27%		-3.06%	-42.90%

02/04	Pulmonx Appoints Mehul Joshi as Chief Financial Officer	MT
02/04	Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Downgrades Pulmonx to Equalweight From Overweight, Cuts Price Target to $14 From $16	23/02	MT
Canaccord Genuity Adjusts Pulmonx's Price Target to $16 From $12, Keeps Buy Rating	22/02	MT
Stifel Adjusts Pulmonx's Price Target to $17 From $15, Keeps Buy Rating	22/02	MT
Wells Fargo Adjusts Pulmonx's Price Target to $16 From $15, Keeps Overweight Rating	22/02	MT
Citigroup Adjusts Pulmonx's Price Target to $17 From $16, Keeps Buy Rating	22/02	MT
Craig-Hallum Adjusts Pulmonx's Price Target to $20 From $18, Keeps Buy Rating	22/02	MT
Craig-Hallum Initiates Pulmonx at Buy With $18 Price Target	05/23/05	MT
Citigroup Raises Price Target on Pulmonx to $16 From $14, Maintains Buy Rating	11/23/11	MT
Piper Sandler Adjusts Pulmonx's Price Target top $15 From $13, Keeps Overweight Rating	03/23/03	MT
Morgan Stanley Adjusts Pulmonx's Price Target to $14 From $11, Keeps Equalweight Rating	03/23/03	MT
Citigroup Adjusts Pulmonx Price Target to $13 From $12, Maintains Buy Rating	03/23/03	MT
Wells Fargo Upgrades Pulmonx to Overweight From Equalweight, Adjusts Price Target to $15 From $10	27/23/27	MT
Morgan Stanley Adjusts Price Target on Pulmonx to $11 From $9.50, Keeps Equalweight Rating	23/23/23	MT
Canaccord Genuity Adjusts Price Target on Pulmonx to $20 From $18, Maintains Buy Rating	23/23/23	MT
Morgan Stanley Adjusts Price Target on Pulmonx to $9.50 From $14, Maintains Equalweight Rating	06/23/06	MT
BofA Securities Downgrades Pulmonx to Underperform From Neutral With $8 Price Target	03/23/03	MT
Wells Fargo Cuts Price Target on Pulmonx to $6 From $13.50, Maintains Equalweight Rating	12/22/12	MT
Citigroup Upgrades Pulmonx to Buy From Neutral, Adjusts Price Target to $10 From $14	12/22/12	MT
Morgan Stanley Adjusts Price Target on Pulmonx to $14 From $19, Maintains Equal-Weight Rating	07/22/07	MT
Piper Sandler Adjusts Price Target on Pulmonx to $13 From $25, Maintains Overweight Rating	04/22/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pulmonx Corporation

Equities

LUNG

US7458481014

Analyst Reco.

Filters